Our new six-liter head. It's out for blood.

Our PR-6 has always been fast. Now it's faster. With a brand-new bloodbank head that combines speed with size. Together, they accelerate six liters to 3000 rpm in 75 seconds. Result: faster processing than any other refrigerated centrifuge on the market. There's more. Versatile PR-6 boasts two timers. One (0-15 minutes) for bloodbank use. The other (0-120 minutes) for all-purpose work up to 6000 rpm and 7900 g. Just set time, speed, and hit the switch. Solid-state control does the job from there. For complete details, send for Bulletin PR-6. Or call your IEC distributor and ask him about our new bloodbank six pack.
To control hyperuricemia in the new "Zyloprim" brand Allopurinol Tablets

xanthine oxidase inhibitor

Reduces uric acid production in patients with certain neoplastic diseases.

The concomitant use of 'Zyloprim' (allopurinol) with cancer chemotherapy has been shown "...to prevent or abort the potentially fatal complications related to acute hyperuricemia resulting from effective antineoplastic therapy..." ¹

'Zyloprim' (allopurinol), an analogue of hypoxanthine, acts on purine catabolism but does not disrupt the biosynthesis of vital purines. 'Zyloprim' (allopurinol) reduces both the serum and urine uric acid levels by inhibiting the production of uric acid.

Because of this unique mode of action, concomitant therapy with 'Zyloprim' (allopurinol) avoids the hazard of excessive urinary excretion of uric acid in patients with neoplastic disease who are particularly susceptible to hyperuricemia and uric acid stone formation during antineoplastic drug therapy.

Contraindications: Pending further investigation, allopurinol is presently contraindicated for use in children with the exception of those with hyperuricemia secondary to malignancy. The drug should not be employed in nursing mothers. Patients who have developed a severe reaction to this drug should not be restarted on the drug.

Warnings: A few cases of reversible clinical hepatotoxicity have been noted in patients taking 'Zyloprim' (allopurinol) and in some patients asymptomatic rises in serum alkaline phosphatase or serum transaminase have been observed. Accordingly, periodic liver function tests should be performed during the early stages of therapy, particularly in patients with pre-existing liver disease. Due to the occasional occurrence of drowsiness, patients should be alerted to the need for due precautions when engaging in activities where alertness is mandatory.

Iron salts should not be given simultaneously with 'Zyloprim' (allopurinol) because animal studies suggested an increase in hepatic iron concentration. This drug should not be administered to immediate relatives of patients with idiopathic hemochromatosis.

Usage in pregnancy and women of childbearing age: Since the effect of xanthine oxidase inhibition on the human fetus is still unknown, 'Zyloprim' (allopurinol) should be used in pregnant women or women of childbearing age only if the potential benefits to the patient are weighed against the possible risk to the fetus.

Precautions: A fluid intake sufficient to yield a daily urinary output of at least two liters and the maintenance of a neutral or, preferably, slightly alkaline urine are desirable to (1) avoid the theoretic possibility of formation of xanthine calculi under the influence of allopurinol therapy and (2) to help prevent renal precipitation of urates in patients receiving concomitant uricosuric agents.

Patients with impaired renal function should be carefully observed during the early stages of allopurinol administration and the drug withdrawn if increased abnormalities in renal function appear, since a few patients with pre-existing renal disease have shown a rise in BUN. Relationship of these observations to the drug have not been established.

Mild reticulocytosis has appeared in some patients, most of whom were receiving other therapeutic agents, so that the significance of this observation is not known.

As with all new agents, periodic determinations of liver and kidney function and complete blood counts should be performed.

In patients receiving 'Purinethol' (mercaptopurine), the concomitant administration of 300-600 mg. of 'Zyloprim' (allopurinol) per day will require a reduction in dose to approximately 1/9 to 1/4 of the usual dose of "Purinethol". Subsequent adjustment of doses of 'Purinethol' should be made on the basis of therapeutic response and any toxic effects.

When allopurinol is used in the treatment of gout, maintenance doses of colchicine generally should be given prophylactically since an increase in acute attacks of gout during the early stages of allopurinol administration have been reported. The use of therapeutic doses of colchicine or anti-inflammatory agents may be required to suppress attacks in some cases. It may require several months to deplete the uric acid pool sufficiently to achieve control of the acute episodes.

In the treatment of gout, concomitant administration of a uricosuric agent with 'Zyloprim' (allopurinol) may result in a decrease in urinary excretion of oxypurines as compared to their excretion with allopurinol alone.
treatment of neoplastic diseases...

- **Leukemias, lymphomas:**
  May be given prophylactically to prevent tissue urate deposition, acute urate nephropathy, or renal calculi in patients with leukemias, lymphomas or certain other malignancies who are receiving cancer chemotherapy or radiation therapy.

- **Polycythemia vera, myeloid metaplasia:**
  For the treatment of secondary hyperuricemia, with or without gout, which occurs in polycythemia vera, myeloid metaplasia, leukemia, or other blood dyscrasias.

- **Concomitant with 'Purinethol' brand Mercaptopurine:**
  May be employed to inhibit the oxidation of 'Purinethol' brand Mercaptopurine — permits use of smaller doses of 'Purinethol'.

Note: This is not an innocuous drug and strict attention should be given to the indications for its use. Complete indications appear in the product packing circular.

However, such combined therapy is not contraindicated and, for many patients, may provide optimum control. Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.

**Adverse reactions:** The most common adverse reaction is skin rash which is most frequently maculopapular in type; exfoliative, urticarial and purpuric lesions have also been reported. Occasionally, fever has accompanied the dermatitis. Nausea, vomiting, diarrhea and intermittent abdominal pain have been reported on occasion. Symptoms suggestive of drug idiosyncrasy characterized by fever, chills, leukopenia or leucocytosis, eosinophilia, arthralgias, skin rash, pruritus, nausea and vomiting have been reported in a few patients. There have been a few additional reports of asymptomatic leukopenia but relationship to 'Zyloprim' (allopurinol) has not been established. There have been single reports of alopecia accompanying dermatitis, peripheral neuritis and bone marrow depression, and a few reports of cataracts. The relationship of 'Zyloprim' (allopurinol) to these events has not been established. Drowsiness has been reported in a few patients on allopurinol.

**Dosage:** The dose of 'Zyloprim' (allopurinol) to accomplish full control of gout and to lower serum uric acid to normal or near-normal levels varies with the severity of the disease. The average is 200 to 300 mg. per day divided into two or three doses for patients with mild gout and 400 to 600 mg. per day for those with moderately severe tophaceous gout. Similar considerations govern the regulation of dosage for maintenance purposes in secondary hyperuricemia. For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg. daily for two or three days is advisable together with a high fluid intake. The minimal effective dose is 100 to 200 mg. daily and the maximal recommended dose is 800 mg. daily.

Divided daily doses are advisable because of the short half-life of the drug. Normal serum urate levels are achieved in 1 to 3 weeks. Children, 6 to 10 years of age, with secondary hyperuricemia associated with malignancies may be given 100 mg. of 'Zyloprim' (allopurinol) three times daily while those under 6 years are generally given 50 mg. three times daily. The response is evaluated after approximately 48 hours of therapy and a dosage adjustment is made if necessary.

In patients who are being treated with uricosuric agents, colchicine, and/or anti-inflammatory agents, it is wise to continue this therapy for several months while adjusting the dosage of 'Zyloprim' (allopurinol) until a normal serum uric acid and freedom from acute attacks have been maintained for several months. A fluid intake sufficient to yield a daily urinary output of at least two liters and the maintenance of a neutral or, preferably, slightly alkaline urine are desirable.

**Preparation:** 'Zyloprim' brand Allopurinol 100 mg. scored tablets, bottles of 100.


Complete information available from your local 'B.W. & Co.' Representative or from Professional Services Department PML.

BURROUGHS WELLCOME & CO. (U.S.A.) INC., Tuckahoe, N. Y.
THE SKIN
A CLINICOPATHOLOGIC TREATISE
Second Edition

By ARTHUR C. ALLEN, M.D., Director of Laboratories, The Jewish Hospital of Brooklyn;
Clinical Professor of Pathology, State University of New York, Downstate Medical
Center, Brooklyn, N. Y.

IN REVIEW
"The second edition has been considerably rewritten and throughout is noticeably
infused with current dermatologic literature and thinking. . . . The author's textual
material is concise, well-informed, and usually affords the essential broad foundation
necessary to understand the development of specific disease states. The photographic
material, consisting of clinical pictures and photomicrographs is exceptionally good.
Dr. Allen is a recognized authority in this field, and it is gratifying to see such a mono-

". . . one of the most ambitious and impressive works to appear under single author-
ship in the past decade. Encyclopedic in the scope and variety of its contents, 'The
Skin' is a veritable one-volume library." — Med. Tribune

"The author has a fluent and engaging style of writing, but the outstanding attribute
of the book is the photographs, especially the clinical and gross pictures. The micro-
scopic illustrations are generally excellent . . . highly recommended." — J.A.M.A.

CONTENTS (section headings)
Embryology, Anatomy and Physiology / Definitions, Regional Distribution of Dermatoses, and
Eponyms / Histologically Identifiable Noninfectious Dermatosis / Lupus Erythematosus, Der-
matomyositis, Scleroderma, and Poikiloderma / Lesions of Collagen and Elastic Tissue / Panniculitides / Dermatoses of Allergic Origin / Vesicular Dermatoses / Nonvesicular Virus
and Rickettsial Diseases / Pyoderma and Specific Bacterial Infections / Tuberculosis, Sarco-
dosis, Berylliosis, and Leprosy / The Treponematosis and Nonspirochetal Venereal Diseases / Mycoses / Eruptions Caused by Protozoa, Arthropods, and Helminths / Psychocutaneous
Disorders and Miscellaneous Desquamative Dermatoses and Genodermatoses / The Vitamins
/ Vascular Disorders / Abnormalities of Pigmentation / Disorders of Cutaneous Appendages / Non-neoplastic Lesions of Oral Mucosa / Verrucae, Epithelial Cysts, and Tumors of Append-
ages / Carcinomas of the Skin and Mucosa, and Miscellaneous Tumors of the Oronasal
Cavity / Nevi and Malignant Melanomas / Tumors of Mesenchymal Tissues / Xanthomatoses
and Lipid and Nonlipid Histiocytes / Tumors of Vessels / Tumors of Hematopoietic Tissues.

1,192 Pages • 2,362 Illustrations • Packed in Slip Case • $48.50

GRUNE & STRATTON, INC. 381 Park Avenue South, New York, N. Y. 10016
REFERENCES*

Lists of references cited in medical text are often in error; yet, many readers judge an article largely by the accuracy with which such material was originally prepared in manuscript and checked in proof. Blood hopes that observance of the following notes to authors will result in more accurate bibliographic information, presented in a consistent style.

Type bibliographies double-spaced under the heading, REFERENCES. See examples below. Note use of the paragraph indentation. Do not underline or use all-capitals.

References should be compiled numerically according to the order of citation in the text. Use initials for the names of cited authors rather than full first names (although full first names of female authors may be used). The abbreviation, "et al.", is permitted in text but not in lists of references.

Abbreviations for titles of medical periodicals should conform to those used in Index Medicus. (A "List of Journals Indexed in Index Medicus"—with abbreviations—is obtainable from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402, at 75 cents.) Note that Blood uses periods for such abbreviations.

Abbreviate book publishers' names by elimination of their initials and such designations as "Company, Inc., Bros., Ltd."

Foreign-language titles of cited books and articles should be given in the original language, followed by a precise English translation in parentheses. Pay particular attention to proper use of accents, capitalization of German nouns, and similar conventions. If the original language uses other than the Roman alphabet, simply give the title in English, followed by a parenthetical note — e.g., (in Russian).

Note that the bibliographic references should be complete, as exemplified below. Note the order of material, style of punctuation and the different use of capital letters for book and journal literature; also Ed. (editor) vs. ed. (edition), etc.

Before submitting the manuscript for publication, check bibliographic numbers and the spelling of authors' names in the text against their form in the References.

EXAMPLES

BOOK (note also handling of "edition" and, only if necessary, of exact page citation):


JOURNAL ARTICLE (note handling of multiple authorship; also use of first page of article only, not inclusive pages):


CONTRIBUTION TO BOOK (note also handling of "Editors" and "Volume"):


*Reprints of this sheet are available without cost from the Editor in Chief or the publisher.
TEXTBOOK OF IMMUNOPATHOLOGY

Edited by:

PETER A. MIESCHER, M.D.
Professor of Hematology; Head,
Division of Hematology,
University Hospital, Geneva, Switzerland

HANS J. MULLER-EBERHARD, M.D.
Scripps Clinic and Research Foundation,
Department of Experimental Pathology,
La Jolla, California

During the past decade immunopathology has rapidly progressed from its classical stage of phenomenological description of immune reactions to the modern era of cellular and molecular analysis of the underlying mechanisms. This development is a reflection of the current, unprecedented advancement of the biomedical sciences. The editors have collected and condensed the body of pertinent information and made it available in the form of a comprehensive textbook.

The purpose of this textbook is to give a critical review of immunopathology with the primary emphasis on those topics which are of relevance to human disease and which, therefore, are of particular interest to clinicians and pathologists.

The first section of the book, General Immunopathology, illuminates the principles which constitute the conceptual basis of immunopathology as a discipline of the biomedical sciences. Here are discussed the mechanisms of immunization and their counterpart, immunologic unresponsiveness; the structure of antibodies and the principles of genetics pertaining to evolution and polymorphism of the immunoglobulins; the various types of immune reactions and the mode of action of cellular and humoral mediators; the mechanisms of production of cell and tissue damage by various immune processes and effector systems. Because of their relevance to human disease, several experimental immune diseases have been treated in detail. For similar reasons, chapters are included which deal with homotransplantation in experimental animals and with the effect of drugs on pathogenic immune phenomena.

The second section of the book, Clinical Immunopathology, is devoted to the discussion of immune reactions in human disease with emphasis being placed on pathogenic reactions. Clinical aspects are discussed only as they are considered essential to the immunologic description of a disease. Wherever latest developments are of significance to the contents of a particular chapter or to the total picture of immunopathology, they are recorded in the form of addenda.

The sixty-four contributions, all by well-known leaders in the field, comprise an exhaustive and detailed study. For all those concerned with immunopathology, this book can serve as a practical guide and as a lasting source of reference.

JUST PUBLISHED

IN TWO VOLUMES—WITH 64 CONTRIBUTIONS

Volume I - 408 pages, illus., $19.75
Volume II - 448 pages, illus., $24.75

GRUN & STRATTON, INC. / NEW YORK & LONDON
Complete Control
FOR COAGULATION PROCEDURES

Dade Reagents provides the products ... and the program ... for complete Quality Control in Coagulation.
Now you have a good reason to change anticoagulants

FENWAL CPD BLOOD-PACK® Units provide a better unit of blood.

From the moment of collection to the day of use, CPD blood more closely approximates the chemistry of normal circulating blood than ACD blood. CPD anticoagulant is an isotonic solution that minimizes trauma to red cells during collection. And, because CPD blood contains 14% less citrate and is 50% less acid than ACD blood, it is particularly applicable in multiple transfusion therapy where citrate toxicity and acidosis may present a problem.

In component therapy, CPD gives excellent preservation of clotting factors in both fresh frozen plasma and AHF concentrate preparations.

And blood collected and stored in Fenwal CPD BLOOD-PACK Units meets all blood bank transfusion standards for 21-day anticoagulants.

CPD—a good reason to change anticoagulants today. Available only in Fenwal BLOOD-PACK Units.

REFERENCES:


Reprints available on request.
Fresh cells weekly are here.

It's a fact! Antigenicity of red cell reagents declines with age! So, if you're the kind of technologist who believes in using the freshest possible blood sample, you'll want to do your screening and serum grouping with the freshest possible cell reagents. With "Fresh Cells Weekly" from Pfizer Diagnostics, you can have ready-to-use reagent red cells delivered to you fresh each week (with two week dating).

Reagents available fresh each week include HEMANTIGEN®, single vial, pooled cells for broad-range antibody detection; PANSCREEN®, single donor, 2-vial antibody screening cells; as well as REFERENCCELS®, our panel of A, A2, B and O cells for complete serum grouping.

"Fresh Cells Weekly" combat the problem of aging cells. They are another blood bank "first" from Pfizer Diagnostics.

For complete information on "Fresh Cells Weekly," write: Dept. FCW, PFIZER DIAGNOSTICS, 300 West 43rd St., New York, N.Y. 10036

Fresher cells give stronger reactions.